ConductScience.org, home

Paper32158481

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.

Galbiati D and 10 others. Drugs Context, 2019. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Papers, record 32158481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32158481

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.
PubMed
Journal
Drugs Context
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.31
iCite
Revised in PubMed
2022-04-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Galbiati DDonata
2Cavalieri SStefano
3Alfieri SSalvatore
4Resteghini CCarlo
5Bergamini CCristiana
6Orlandi EEster
7Platini FFrancesca
8Locati LLaura
9Giacomelli LLuca
10Licitra LLisa
11Bossi PPaolo

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131051028Systemic therapy for advanced cutaneous squamous cell carcinoma.Semin Cutan Med Surg2019https://conductscience.org/library/papers/31051028PubMed
222484186Chemotherapy of squamous cell carcinoma of the skin.Semin Oncol2012https://conductscience.org/library/papers/22484186PubMed
325716064Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review.Australas J Dermatol2015https://conductscience.org/library/papers/25716064PubMed
415865067Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin.Anticancer Res2005https://conductscience.org/library/papers/15865067PubMed
511274625Cutaneous squamous-cell carcinoma.N Engl J Med2001https://conductscience.org/library/papers/11274625PubMed
629734047Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.Eur J Cancer2018https://conductscience.org/library/papers/29734047PubMed
731163235Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.J Am Acad Dermatol2020https://conductscience.org/library/papers/31163235PubMed
831587382Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.J Eur Acad Dermatol Venereol2020https://conductscience.org/library/papers/31587382PubMed
930672860Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center.Dermatol Surg2019https://conductscience.org/library/papers/30672860PubMed
102004320Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin.Cancer1991https://conductscience.org/library/papers/2004320PubMed
1122592943The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors.J Surg Oncol2012https://conductscience.org/library/papers/22592943PubMed
1228384639Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.Dermatology2016https://conductscience.org/library/papers/28384639PubMed
1329957662Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab.Dermatol Surg2019https://conductscience.org/library/papers/29957662PubMed
141698529Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.Cancer1990https://conductscience.org/library/papers/1698529PubMed
1510776981Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged.Am J Clin Oncol2000https://conductscience.org/library/papers/10776981PubMed
1622534799Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma.Int J Clin Oncol2013https://conductscience.org/library/papers/22534799PubMed
176326362Diagnosis of human tumors. Case 10: Pseudosarcomatous squamous cell carcinoma.Ultrastruct Pathol1983https://conductscience.org/library/papers/6326362PubMed
1822251204A systematic review of worldwide incidence of nonmelanoma skin cancer.Br J Dermatol2012https://conductscience.org/library/papers/22251204PubMed
1929579331Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.Cancer2018https://conductscience.org/library/papers/29579331PubMed
2022360041Cutaneous squamous cell carcinoma associated with proliferation of osteoclast-like giant cells.J Pak Med Assoc2011https://conductscience.org/library/papers/22360041PubMed

See all 28 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
41333481Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment.Front Immunol2025https://conductscience.org/library/papers/41333481PubMed
40632444The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.Curr Treat Options Oncol2025https://conductscience.org/library/papers/40632444PubMed
39072317Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab).Front Immunol2024https://conductscience.org/library/papers/39072317PubMed
35408839Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.Int J Mol Sci2022https://conductscience.org/library/papers/35408839PubMed
35158897Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma.Cancers (Basel)2022https://conductscience.org/library/papers/35158897PubMed
34877077Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma.Dermatol Pract Concept2021https://conductscience.org/library/papers/34877077PubMed
32911687The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma.Cancers (Basel)2020https://conductscience.org/library/papers/32911687PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32158481

GET https://conductscience.org/api/papers/v1/32158481/references?page=2